The heart is an organ upon which life itself depends. With a commitment to providing new treatment options for heart failure and saving many lives, iHeart Japan is developing regenerative medicine products using iPS cells. Our product, IHJ-301, combines cells derived from iPS cells, including cardiomyocytes and endothelial cells, with a biomaterial, enabling long-term survival following implantation onto the heart and is expected to deliver strong therapeutic efficacy. Going forward, we plan to commercialize this product in Japan and internationally, with the aim of realizing a society in which patients can be saved without heart transplantation.
再生医療を“特別な治療″から“当たり前の治療″にするiHeart Japan株式会社（本社：京都市、代表者：角田健治、以下「当社」。）は、ベンチャーキャピタルなどを引受先とした第三者割当増資によって８億円の資金を...
再生医療を“特別な治療″から“当たり前の治療″にするiHeart Japan株式会社（京都市、代表者：角田健治、以下「当社」）は、当社が開発しているヒトiPS細胞由来心血管系細胞多層体＊１（以下「IHJ-301」）を、世界...
再生医療を “特別な治療” から “当たり前の治療” にする iHeart Japan 株式会社（以下では「当社」）は、当社代表取締役が2024年6月6日の齋藤健経済産業大臣（以下では「齋藤大臣」）のシンガポール訪問に併せて...
その表彰式および受賞者発表が、2022年9月28日に国立京都国際会館で開かれる京都商工会議所創立140周年記念事業「アニバーサリー交流会」において、催されます。お気軽にご参加くだい。詳細および来場者登録方...
再生医療を “特別な治療” から “当たり前の治療” にするiHeart Japan株式会社（本社：京都市，代表者：角田健治，以下では「当社」）は，ベンチャーキャピタルなどを引受先とした第三...
  今後、京大病院チームは厚生労働大臣に臨床研究の計画を提出する予定です。提出された計画は再生医療等提供基準に適合しているか審議され、その結果、厚生労働大臣から計画の変更等を命じられる場合があ...
当社との提携による事業として、タカラバイオ株式会社が『3D模擬心臓壁（MiraCell Cardiomyocytes 3D）を用いた心毒性試験』の提供を開始しましたので、お知らせいたします。 タカラバイオ株式会社は、当...
当社は、『ヒトiPS細胞由来心血管系細胞多層体（以下、「IHJ-301」とします。）』を心不全の治療に用いる臨床研究を、大学病院等の協力を得て、行うことを計画していますが、医療機関以外の施設が再生医療に用い...
この事業では「ベンチャー企業を含む民間企業を対象とし、企業が有する臨床開発前段階のシーズを迅速に臨床開発に進めるための研究開発（以上、AMEDウェブ・ページから引用）」を行い、2018年10月から2020年3月ま...
L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
With more than 30 years of experience in developing tactile and sensory measurement technologies, Jun Wada founded Hapquitous in 2023 upon turning 60. Guided by the mission of “bringing the potential of sensation and perception to anyone, anywhere,” Hapquitous developed Pain Compass®, a novel device based on the Thermal Grill Illusion (TGI). The system provides a three-minute assessment that objectively evaluates stress-related hypersensitivity in the brain and visualizes presenteeism—conditions that typically remain hidden in the workplace. Hapquitous offers an integrated solution that connects measurement → intervention (acupuncture, exercise, psychological support) → follow-up assessment, enabling early detection and improvement of employee well-being. Hapquitous is currently conducting collaborative research with ten institutions, including Kyoto Tachibana University, Kio University, and the University of Tokyo School of Medicine.
Leveraging world-leading autophagy measurement technology, we provide end-to-end solutions from material evaluation and supplement/cosmetic development to drug discovery research. A startup demonstrating results in international competitions, aiming for the societal implementation of extended healthy lifespans.
We offer technology licensing to various companies for a "perfect alcohol-based sanitizer" effective against food poisoning bacteria that are resistant to standard alcohol sanitizers. The reason these bacteria survive even at 100℃ is their ability to synthesize a robust structure called a spore. We have discovered that substance Y inhibits spore formation, and by incorporating it into alcohol-based sanitizers sterilization becomes possible. Furthermore, substance Y is safe and secure; when added to food products, the bacteria can be killed by heating at 100℃. We are therefore also proposing a new sterilization method.